EMP16

Oral, safe, and effective solution for long-term weight-loss maintenance – closing the gap in current drug development for obesity

Obesity: A Global Health Challenge 

Obesity is a chronic, complex condition affecting both individual and public health. Driven by genetic, environmental, and lifestyle factors, it is one of the fastest-growing health challenges worldwide. Effective management requires psychological support, medical treatment, and sustainable lifestyle changes.

The Need for Better Weight-Loss Maintenance

Although there are anti-obesity medications (AOMs) that are very effective and the general obesity landscape has become increasingly competitive with new drugs, there is an emerging gap for a therapeutic option enabling durable maintenance of metabolic health. The lack of maintenance options, physicians resort to using reduced dosages or extended dosing intervals, but still up to 80% of patients discontinue anti-obesity medications (AOMs) within two years and regain ~2/3rds of the weight they had lost. 

Introducing EMP16

EMP16 is a revolutionary oral therapy designed to support long-term weight-loss maintenance following GLP-1–induced weight reduction. Its proprietary formulation delays digestion and absorption toward the end of the small intestine, optimizing effects throughout the gastrointestinal system. EMP16 combines two locally active and established drugs—orlistat and acarbose—in a modified-release formulation that maximizes efficacy while improving tolerability. It offers proven efficacy and favorable safety.